Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortin GlobalBOM:539287 +0.46%41 Market Cap is ₹123.19 Mil as of Jul. 23, 2026. GuruFocus rates BOM:539287 with a GF Score™ of 41/100 and a GF Value™ of ₹2.52 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Ortin Global ranks worse than 95.99% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ortin Global's share price for the quarter that ended in Mar. 2026 was ₹14.15. Ortin Global's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 8.13 Mil. Therefore, Ortin Global's market cap for the quarter that ended in Mar. 2026 was ₹115.05 Mil.
Ortin Global's quarterly market cap
increased
from Sep. 2025 (₹97.90 Mil) to Dec. 2025 (₹120.34 Mil) but then
declined
from Dec. 2025 (₹120.34 Mil) to Mar. 2026 (₹115.05 Mil).
Ortin Global's annual market cap
declined
from Mar. 2024 (₹144.73 Mil) to Mar. 2025 (₹81.15 Mil) but then
increased
from Mar. 2025 (₹81.15 Mil) to Mar. 2026 (₹115.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ortin Global's Enterprise Value for Today is ₹127.18 Mil.
Ortin Global (BOM:539287) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ortin Global Market Cap Related Terms
Ortin Global Market Cap Historical Data
* Premium members only.
The historical data trend for Ortin Global's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortin Global Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ortin Global's Market Cap distribution charts can be found below:
* The bar in red indicates where Ortin Global's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ortin Global's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortin Global (BOM:539287) has a Market Cap of ₹123.19 Mil as of Jul. 23, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ortin Global and its competitors. According to the industry distribution chart, Ortin Global ranks #982 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 96%.
Is Ortin Global's Market Cap too high?
Ortin Global's current Market Cap is ₹123.19 Mil. Based on the distribution chart, Ortin Global ranks #982 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ortin Global has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ortin Global ranks #982 out of 1023 companies for Market Cap. This places Ortin Global in the lower half of its industry. The industry median Market Cap is 211.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 211.56, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ortin Global and its competitors. For the Drug Manufacturers industry, the median Market Cap is 211.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortin Global's current Market Cap is ₹123.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (BOM:539287) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.52, compared to a current price of ₹15.15 — trading 501.2% above its estimated fair value. The current Market Cap is ₹123.19 Mil. Ortin Global's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ortin Global (BOM:539287), the current Market Cap is ₹123.19 Mil as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortin Global (BOM:539287) Overvalued in 2026?
Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued.
The current stock price of ₹15.15 is trading 501.2% above its estimated GF Value™ of ₹2.52.
GuruFocus considers Ortin Global to be Significantly Overvalued.
Key valuation signals for BOM:539287:
Market Cap: ₹123.19 Mil
GF Value™: ₹2.52 vs. price of ₹15.15 (501.2% above fair value)
No single metric tells the full story. See the BOM:539287 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
41GF Score
Get the complete analysis for BOM:539287
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539287 has been successfully added to your 
